作者
Naseema Gangat, Christian Marinaccio, Ronan Swords, Justin M Watts, Sandeep Gurbuxani, Alfred Rademaker, Angela J Fought, Olga Frankfurt, Jessica K Altman, Qiang Jeremy Wen, Noushin Farnoud, Christopher A Famulare, Akshar Patel, Roberto Tapia, Rangit R Vallapureddy, Stephanie Barath, Amy Graf, Amy Handlogten, Darci Zblewski, Mrinal M Patnaik, Aref Al-Kali, Yvonne Trang Dinh, Kristen Englund Prahl, Shradha Patel, Juan Carlos Nobrega, Dalissa Tejera, Amber Thomassen, Juehua Gao, Peng Ji, Raajit K Rampal, Francis J Giles, Ayalew Tefferi, Brady Stein, John D Crispino
发表日期
2019/8/15
期刊
Clinical cancer research
卷号
25
期号
16
页码范围
4898-4906
出版商
American Association for Cancer Research
简介
Purpose
Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic complications, and a risk of evolution to acute leukemia. The JAK kinase inhibitor ruxolitinib provides therapeutic benefit, but the effects are limited. The purpose of this study was to determine whether targeting AURKA, which has been shown to increase maturation of atypical megakaryocytes, has potential benefit for patients with myelofibrosis.
Patients and Methods
Twenty-four patients with myelofibrosis were enrolled in a phase I study at three centers. The objective of the study was to evaluate the safety and preliminary efficacy of alisertib. Correlative studies involved assessment of the effect of alisertib on the megakaryocyte lineage, allele burden, and fibrosis.
Results
In addition to being well …
学术搜索中的文章
N Gangat, C Marinaccio, R Swords, JM Watts… - Clinical cancer research, 2019